1. Home
  2. SOPA vs QUCY Comparison

SOPA vs QUCY Comparison

Compare SOPA & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Society Pass Incorporated

SOPA

Society Pass Incorporated

HOLD

Current Price

$0.42

Market Cap

6.9M

Sector

Technology

ML Signal

HOLD

Logo Mainz Biomed N.V. Ordinary Shares

QUCY

Mainz Biomed N.V. Ordinary Shares

N/A

Current Price

$0.49

Market Cap

5.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SOPA
QUCY
Founded
2018
2008
Country
Singapore
Germany
Employees
N/A
13
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
5.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SOPA
QUCY
Price
$0.42
$0.49
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$22.50
N/A
AVG Volume (30 Days)
2.6M
336.2K
Earning Date
05-19-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,171,635.00
N/A
Revenue This Year
$2.43
$74.34
Revenue Next Year
$71.20
$171.48
P/E Ratio
N/A
N/A
Revenue Growth
45.00
N/A
52 Week Low
$0.32
$0.40
52 Week High
$6.28
$0.74

Technical Indicators

Market Signals
Indicator
SOPA
QUCY
Relative Strength Index (RSI) 39.31 43.42
Support Level $0.34 $0.43
Resistance Level $0.69 $0.53
Average True Range (ATR) 0.08 0.07
MACD 0.02 0.01
Stochastic Oscillator 32.36 25.20

Price Performance

Historical Comparison
SOPA
QUCY

About SOPA Society Pass Incorporated

Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.

About QUCY Mainz Biomed N.V. Ordinary Shares

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: